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Abstract
Background: Doherty and Zinkernagel, who discovered that antigen presentation is restricted by
the major histocompatibility complex (MHC, called HLA in humans), hypothesized that individuals
heterozygous at particular MHC loci might be more resistant to particular infectious diseases than
the corresponding homozygotes because heterozygotes could present a wider repertoire of
antigens. The superiority of heterozygotes over either corresponding homozygote, which we term
allele-specific overdominance, is of direct biological interest for understanding the mechanisms of
immune response; it is also a leading explanation for the observation that MHC loci are extremely
polymorphic and that these polymorphisms have been maintained through extremely long
evolutionary periods. Recent studies have shown that in particular viral infections, heterozygosity
at HLA loci was associated with a favorable disease outcome, and such findings have been
interpreted as supporting the allele-specific overdominance hypothesis in humans.
Methods: An algebraic model is used to define the expected population-wide findings of an
epidemiologic study of HLA heterozygosity and disease outcome as a function of allele-specific
effects and population genetic parameters of the study population.
Results:  We show that overrepresentation of HLA heterozygotes among individuals with
favorable disease outcomes (which we term population heterozygote advantage) need not indicate
allele-specific overdominance. On the contrary, partly due to a form of confounding by allele
frequencies, population heterozygote advantage can occur under a very wide range of assumptions
about the relationship between homozygote risk and heterozygote risk. In certain extreme cases,
population heterozygote advantage can occur even when every heterozygote is at greater risk of
being a case than either corresponding homozygote.
Conclusion:  To demonstrate allele-specific overdominance for specific infections in human
populations, improved analytic tools and/or larger studies (or studies in populations with limited
HLA diversity) are necessary.
Background
The role of genetics in modulating the immune response
to infectious diseases is a topic of longstanding interest
among epidemiologists, clinicians, population geneti-
cists, and immunologists [1,2]. Zinkernagel and Doherty's
Nobel Prize-winning discovery that cellular immunity to
viral infections was "restricted" by the highly variable
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proteins of the Major Histocompatibility Complex
(MHC) brought the field of immunogenetics into sharper
focus [3]. Their demonstration that T lymphocytes recog-
nize virus antigens displayed on a host cell "in the context
of" MHC proteins immediately suggested the idea that ge-
netic differences at the loci encoding the MHC might
modulate the intensity and effectiveness of host response
to infection.
The relationship between MHC genotype and infectious
disease resistance can take several forms. Most simply, in-
dividual MHC alleles may be especially effective, or espe-
cially ineffective, at presenting antigens from particular
infections, so that carrying one or two copies of a given
MHC allele might predispose an infected individual to a
more or less favorable disease outcome. A second, distinct
but compatible hypothesis was suggested by Doherty and
Zinkernagel soon after their discovery of MHC restriction:
since each MHC allele provides an infected individual
with the ability to present a particular set of antigens, in-
dividuals who are heterozygous (say, genotype XY) at a
particular MHC locus may mount a more vigorous im-
mune response to a given infection, resulting in a better
outcome, than individuals who are homozygous for ei-
ther of the corresponding alleles (XX or YY) [4].
Determining whether either or both of these mechanisms
operates for a particular disease is of interest for a variety
of basic and applied purposes. Epidemiologically, HLA
genotype partially accounts for inter-patient variation in
disease severity or progression rates for such long-term vi-
ral infections as HIV, human T-cell lymphotropic virus,
type 1 (HTLV-1), and hepatitis B and C [5–9]. Such asso-
ciations can lead to mechanistic studies to test hypotheses
about the immunologic basis of these associations
[10,11] and could, in principle, be used to help predict in-
dividual prognoses [12,13]. At least one clinical study has
shown that HLA genotype affects the immune response to
a candidate HIV vaccine [14]. Vaccine designers have be-
gun to take account of the HLA genotypes of potential re-
cipients in choosing antigens for inclusion in a vaccine
[15], and it has been suggested that HLA genotype be con-
sidered in designing samples for inclusion in epidemio-
logic studies of anti-HIV immune response [12]. In
evolutionary biology, the possibility that HLA heterozy-
gotes are more resistant to infectious diseases is the basis
for a leading hypothesis to explain the unparalleled diver-
sity of HLA genes (and MHC genes in other vertebrates)
and the maintenance of this diversity over long periods of
evolutionary time [16].
Of the two ways described above in which MHC genotype
may affect disease outcome, the first – association be-
tween a particular allele and disease outcome – has been
repeatedly documented in human populations by various
methods of genetic epidemiology [17]. The second kind
of effect, more vigorous immune responses to a pathogen
by a heterozygote as compared to homozygotes for the
same alleles, which we term "allele-specific overdomi-
nance," has been suggested by several animal studies [18–
21], although none of these studies is unambiguous (see
DISCUSSION). There have been no studies (to our knowl-
edge) in humans that directly compare the infectious dis-
ease outcomes of heterozygotes to those of homozygotes
for the same alleles (interestingly, the situation is very dif-
ferent for autoimmune diseases; see DISCUSSION for fur-
ther consideration).
As an alternative to directly examining the hypothesis of
allele-specific overdominance, several investigators have
compared the infectious disease outcomes of heterozy-
gotes at a given HLA locus, as a group, to the outcomes of
homozygotes at the same locus, as a group. In many cases,
heterozygotes as a group have shown better infectious dis-
ease outcomes (slower disease progression or more rapid
clearance of viral infection) than homozygotes as a group
[5,6,8,9,14,22], a phenomenon we call "population het-
erozygote advantage." Because these studies group all ho-
mozygotes and group all heterozygotes, they do not, in
fact, test the hypothesis of allele-specific overdominance,
which is conditional on the alleles involved. Although
population heterozygote advantage and allele-specific
overdominance are different [10], reports of population
heterozygote advantage have frequently been interpreted
as confirmations of the Doherty-Zinkernagel hypothesis
of allele-specific overdominance.
In this report, we show that although population hetero-
zygote advantage is compatible with allele-specific over-
dominance, it is also compatible with the opposite; i.e.,
population heterozygote advantage could arise in a popu-
lation in which every heterozygote had a worse disease
outcome than either of the corresponding homozygotes
("allele-specific underdominance"). The reason for this
disconnect is an unusual form of confounding in which
particular (protective or detrimental) alleles are over- or
under-represented among heterozygotes, as we discuss be-
low; an additional factor that may be involved results
from the effects of dominance in creating an asymmetry
between homozygotes and heterozygotes. As we have sug-
gested above, it is biologically and epidemiologically use-
ful to determine (a) the beneficial or harmful effects of
specific alleles, and (b) the effects of heterozygosity, such
as allele-specific overdominance; we show here that un-
conditional comparisons of all heterozygotes to all ho-
mozygotes can reflect either or both of these, and cannot
distinguish them. To measure the quantitites of direct in-
terest, analyses that compare disease outcomes condition-
al on the alleles involved, rather than groupedBMC Medical Genetics 2003, 4 http://www.biomedcentral.com/1471-2350/4/2
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comparisons of heterozygotes to homozygotes, will be
more informative.
In the first section below, we outline a general model for
the relationship between genotype at a particular HLA lo-
cus and infectious disease outcome (which we dichot-
omize into favorable and unfavorable), and we use the
model to define the conditions under which population
heterozygote advantage is expected. We show that, de-
pending on allele frequencies at the HLA locus of interest,
population heterozygote advantage may occur when there
is allele-specific overdominance, but may also occur un-
der other conditions, including allele-specific underdom-
inance. Two examples are given to illustrate the reasons
for the lack of concordance between population and al-
lele-specific effects. In the Discussion, we suggest some
possible approaches for estimating allele-specific effects.
General Model
To determine the precise conditions under which popula-
tion heterozygote advantage will be observed, we consider
a general model that predicts the expected outcome of a
comparison between heterozygotes and homozygotes in
an epidemiological study as a function of (i) the frequen-
cies of resistant and susceptible alleles at a particular locus
and (ii) the relationship between genotype at that locus
and phenotype. Note that this is not a model for the evo-
lution of genotype frequencies or for the maintenance of
MHC heterozygosity, but simply an algebraic framework
for predicting the outcome of an epidemiological study of
the type cited above, given current allele frequencies and
genotype-phenotype mappings.
The model is summarized in Table 1. Suppose that indi-
vidual alleles of a particular locus confer either suscepti-
bility or resistance to a given disease, and that there are m
resistance alleles, R1,R2,.,Rm with frequencies p1,p2,.,pm in
the population, and n susceptibility alleles S1,S2,.,Sn with
frequencies q1,q2,.,qn. Let   be the total frequency
of resistant alleles, and   be the total frequency of
susceptible alleles, with p  +  q  = 1. Further, define
 and   are the sums of squared fre-
quencies of the resistant and susceptible alleles, respec-
tively. We assume Hardy-Weinberg genotype frequencies
[23] throughout. Thus, Π is the frequency of RR homozy-
gotes and is an inverse measure of the diversity of resistant
alleles, while Θ, the frequency of SS homozygotes, is an
inverse measure of the diversity of susceptible alleles.
We assume that SS homozygotes have a probability x of a
favorable disease course, and that SS heterozygotes (carry-
ing two different susceptible alleles), SR heterozygotes, RR
heterozygotes, and RR homozygotes have probabilities ax,
bx, cx, and dx respectively (see Table 1). To give meaning
to the notions of resistant and susceptible alleles, we as-
sume d > 1 (RR homozygotes do better than SS homozy-
gotes) and a ≤ b ≤ c (given that one is heterozygous, more
R alleles are better). This model can accommodate domi-
nance (a = 1; b = c = d), additivity (a = 1;c = d; b = (1 + d)/
2), or recessiveness (a = b = 1 and c = d) of the resistant al-
leles. It can also accommodate overdominance of the re-
sistant alleles (a  > 1; b  >d;  c  >d), in which each
heterozygote does better than either corresponding ho-
mozygote, and underdominance, in which each heterozy-
gote does worse than either corresponding homozygote (a
< 1; b < 1; c <d). In this model, susceptibility and resistance
are relative and simply refer respectively to lower and
higher probabilities of favorable disease course, given in-
fection. For simplicity, we assume that all S alleles are
equivalent and all R alleles are equivalent; our
conclusions could obviously be generalized to cases
where there is a whole range of effects for different alleles.
Under these assumptions, we can calculate fhom and fhet,
the probability of a favorable disease course for homozy-
gotes (the first and fifth classes in Table 1) and for hetero-
zygotes (the 2nd, 3rd, and 4th classes in Table 1).
The relative risk (RR) of a favorable outcome for a hetero-
zygote compared to a homozygote is defined as:
Population heterozygote advantage corresponds to RR >
1. Various formulations for relative risk (or odds ratio,
used in case-control studies, such as [6]) are used in stud-
ies of HLA heterozygosity and disease outcome, but in all
cases the cutoff is one and a value larger or smaller than
one (depending on the precise definition used) corre-
sponds to population heterozygote advantage. Using the
relative risk equation above, it can be shown by taking
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partial derivatives with respect to the parameters p, Π and
Θ, that (under the assumptions stated above) the relative
risk increases with p and Θ and decreases with Π. Thus,
population heterozygote advantage is most likely to be
observed when resistant alleles are common (p large) but
highly diverse (Π is small), and when susceptible alleles
are not diverse (large Θ). These trends can be understood
intuitively. Homozygotes will be predominantly resistant
if R alleles are common and have little diversity and sen-
sitive when S alleles are common and have little diversity.
Heterozygotes will be predominantly resistant if R alleles
are highly diverse and sensitive if S alleles are highly
diverse.
Figure 1 shows the parameter regions in which population
heterozygote advantage is expected and those in which
the contrary is expected: homozygotes on average are
more likely to have a favorable disease course. Each panel
reflects a different assumption about the true genetic basis
of resistance – assuming that resistant alleles are over-
dominant; dominant; additive; recessive; or underdomi-
nant. In each case, population heterozygote advantage,
shown as the black region and corresponding to RR > 1, is
most likely when resistant alleles are highly diverse and
susceptible alleles have low diversity (bottom right of
each panel).
Figure 1 shows that allele-specific overdominance (the bi-
ological phenomenon of interest) and population hetero-
zygote advantage (the finding of epidemiological studies
such as those cited above) are two different things. Popu-
lation heterozygote advantage (black) may be observed
even when resistance is not overdominant, but only dom-
inant, additive, recessive or only underdominant, as long
as allele frequencies are sufficiently far toward the lower
right of the parameter space (high diversity of resistant al-
leles and low diversity of susceptible alleles). Figure 1
shows that this is possible under a fairly broad range of
parameter combinations (i.e., there are substantial black
areas in the dominant, additive and recessive panels).
The converse is also true, though only in what seem to be
very special circumstances. That is, even when allele-spe-
cific overdominance holds, it is possible that heterozy-
gotes on average will do worse than homozygotes, so
population heterozygote advantage will not be observed.
This occurs with genotype frequencies sufficiently far to-
ward the top left of Figure 1, with a high diversity of sus-
ceptible alleles and low diversity of resistant ones. This
occurs only rarely for the parameter values we have cho-
sen (most of the leftmost panel is black), and this seems
to be the case for a broad range of parameter values.
Although neither population heterozygote advantage nor
allele-specific overdominance implies the other, the two
phenomena are of course related. Specifically, the condi-
tions to observe population heterozygote advantage are
broadest when allele-specific overdominance holds and
become narrower as the underlying genetics becomes
more "different" from overdominance of resistance (dom-
inance -> additivity -> recessiveness -> underdominance).
Two Examples
The intuition behind our result that population heterozy-
gote advantage need not reflect allele-specific overdomi-
nance can be seen in two simple examples.
Example 1: Suppose that there are two alleles, each at 50%
frequency in the population, one (R) conferring resistance
and one (S) conferring susceptibility in the homozygous
state. Population heterozygote advantage will be observed
if the probability of a favorable outcome for heterozygotes
is greater than the arithmetic mean of the probabilities of
favorable outcomes for RR homozygotes and for SS ho-
mozygotes. In this situation, population heterozygote ad-
vantage does not require overdominance, but merely
allele effects that are more than additive (partial domi-
nance). Dominance of particular HLA alleles conferring
resistance, and/or recessiveness of susceptibility (poor
outcome) alleles, have been documented for schisto-
somiasis [24], leprosy [25], acute lymphoblastic leukemia
Table 1: Frequency and disease risk of 5 classes of genotypes under the model.
Class Susceptible 
homozygotes
Heterozygote of sus-
ceptible alleles
Heterozygote with 
one R and one S allele
Heterozygote of 
resistant alleles
Resistant 
homozygotes
Genotype SiSi SiSi, i ≠ jR iSj RiRj, i ≠ jR iRi
Frequency Θ q2 - Θ 2 pq p2 - ΠΠ
Probability of Favora-
ble Outcome
x a xb xc xd x
Notation: Frequency of allele Si is qi; frequency of allele Ri is pi. p =  pi; q =  qi = 1 - p;  ;  . The subscripts of R 
alleles and the subscripts of the S alleles are unrelated.
i
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(for which an infectious cause is hypothesized) [26], and
hepatitis B (in this case the outcome was vaccine respon-
siveness) [27].
When allele frequencies are equal, as in Example 1, partial
dominance is sufficient to create population heterozygote
advantage [10,11]. When allele frequencies differ, the
conditions for population heterozygote advantage may
become broader or narrower. This can be seen in a second
deliberately extreme example.
Example 2: Suppose there are 10 alleles, each with fre-
quency 5%, each conferring resistance to a particular dis-
ease, and one allele, with frequency 50%, conferring
susceptibility. In the notation of Table 1, this corresponds
to p = q = 0.5; Π = (10)(.05)2 = 0.025; Θ = 0.25. In this
case, >90% of homozygotes in the population will be ho-
mozygous for a susceptible allele, since the frequency of
SS homozygotes is Θ = 0.25, while the frequency of RR ho-
mozygotes is Π = 0.025. In contrast, 100% of heterozy-
gotes will have at least one resistant allele. In
epidemiological terms, this is a form of confounding, in
which possession of a resistant allele is positively associat-
ed with heterozygosity (the exposure of interest) and pos-
itively associated with having a favorable disease course
(the outcome of interest). Because of this confounding,
under some parameter values, population heterozygote
advantage can occur even when heterozygotes are not at
an advantage relative to their corresponding homozy-
gotes. Specifically, population heterozygote advantage
may be observed when resistance is additive (heterozy-
gotes have risks equal to the average of the risks of the cor-
responding homozygotes), when resistance is recessive, or
even when it is underdominant (heterozygotes have high-
er risk of disease than either corresponding homozygote).
Continuing this example, suppose that the resistant alleles
are recessive to the susceptible one, so that individuals
with one or two copies of the susceptible allele have favo-
rable outcomes with probability .3 and individuals with
two resistant alleles have favorable outcomes with proba-
bility .7; these assumptions correspond to x = 0.3; a = b =
1; c = d = 2.33. In this example, there are no SS heterozy-
gotes since there is only one S allele; SR heterozygotes
make up 50% of the population (2pq = 0.5), while RR het-
erozygotes (carrying two different R alleles) make up p2 -
Π = 0.225 = 22.5% of the population. The probability of
a favorable outcome for heterozygotes will be the weight-
ed average of the probabilities of a favorable outcome for
SR and RR heterozygotes (using equation 1):
For homozygotes (using equation 2), the probability of a
favorable outcome fhom will be the weighted average of the
probabilities for SS homozygotes (25% of the popula-
tion) and for RR homozygotes (2.5% of the population):
Figure 1
Population heterozygote advantage as a function of allele-specific effects and allele frequencies. Parameter 
regions in which heterozygotes will on average have a higher probability of a favorable disease outcome than homozygotes 
(regions of population heterozygote advantage) are shown in black. Population heterozygote advantage occurs when diversity 
of resistant alleles is sufficiently high and diversity of susceptible alleles is sufficiently low i.e., toward the bottom right of the 
parameter space in each panel of the figure. Different panels indicate various assumptions about the genotype-specific relative 
risks a-d (defined in Table 1). Parameters: Overdominant (a = 1.1, b = 1.6, c = 2, d = 1.5); dominant (a = 1, b = c = d); additive 
(a = 1, b = (1 + c)/2, c = d); recessive (a = b = 1, c = d); underdominant (a = 0.5, b = 0.9, c = 1.4, d = 1.5). These curves are 
drawn for p = 0.5. Dominant, additive and recessive curves are valid for all possible values of the free parameters, while under-
dominant and overdominant curves are examples whose positions depend on the particular values of the parameters a, b, c and 
d.
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Thus, heterozygotes on average will be 1.26 times more
likely to have a favorable outcome, even though each het-
erozygote has the same outcome as if s/he were ho-
mozygous for the worse of the two alleles s/he carries. In
epidemiological terms, heterozygotes would have a rela-
tive risk of 0.87 of an unfavorable outcome compared to
homozygotes.
Both of these examples were chosen for the purposes of
clarity, rather than for precise reflection of the allele fre-
quencies in real populations; in particular, few if any pop-
ulations have a single HLA allele with a frequency of 50%.
Moreover, we have simplified the effects of alleles into
two categories, resistant and susceptible (R and S), which
are simply relative notions. In fact, real alleles will likely
have a spectrum of effects, ranging from highly resistant,
to highly susceptible, with some alleles having "no effect."
Note, however, that "no effect" is also a relative term, and
refers to an allele whose effect on disease outcome is close
to the population average.
Discussion
The foregoing examples show that the finding of popula-
tion heterozygote advantage, as in the infectious disease
studies cited, does not support an inference of allele-spe-
cific overdominance, the condition of primary interest as
an immunological hypothesis and a mechanism for the
maintenance of MHC diversity. Put another way, popula-
tion heterozygote advantage may appear due to a combi-
nation of the two distinct mechanisms we defined in the
Introduction: the protective or detrimental effects of par-
ticular alleles (R and S alleles in our model), and the ef-
fects of heterozygosity itself. The effects of R and S alleles
appear as effects of heterozygosity vs. homozygosity be-
cause heterozygotes and homozygotes will in general car-
ry different distributions of S and R alleles; thus, in an
analysis that fails to condition on the alleles carried, het-
erozygosity is confounded with the alleles carried.
One advantage of correctly separating the effects of indi-
vidual alleles from the effects of heterozygosity condition-
al on those alleles, is that each of these measures is a
characteristic of an individual, rather than a population.
For example, if genotypes XX, XY and YY have relative
risks 0.6, 2.1, and 1 for clearance of a viral infection, then
this should hold true regardless of who else is in the pop-
ulation. In contrast, we have shown that population het-
erozygote advantage depends on not only the effects of
individual genotypes on disease outcome, but also on al-
lele frequencies. Therefore, even if biological and epide-
miologic mechanisms were identical in two populations,
but allele frequencies differed in those two populations, it
would be perfectly reasonable to find population hetero-
zygote advantage in one but not the other.
The problem we have described with measuring popula-
tion heterozygote advantage is not in principle limited to
susceptibility/resistance studies of infectious diseases. In
principle, the same problem could occur in any study of
HLA associations with disease outcome. Interestingly,
however, in our review of the literature on HLA-chronic
disease associations, we have found no examples of the
problem. Moreover, direct estimates of the allele-specific
effects of heterozygosity (relative to the corresponding ho-
mozygotes), nearly absent in the infectious disease-HLA
literature, are frequently found in studies of HLA genotype
and chronic (mostly autoimmune) diseases [28–30]. We
do not know the reason for this difference in approach,
but suspect that some infectious disease investigators, in-
formed by the evolutionary hypothesis of overdominance
for infectious disease resistance and by animal studies,
may have a special interest in detecting effects of heterozy-
gosity per se. Many studies of HLA-autoimmune disease
associations, on the other hand, seem to focus more on
the effects of individual alleles and, having established
these, move on to investigate the dependence of these ef-
fects on genetic modifiers, including the identity of the in-
dividual's other allele at the same locus.
We have shown that when allele-specific overdominance
exists, it will often be manifest as population heterozygote
advantage, but that a finding of population heterozygote
advantage may be consistent with other patterns of allele-
specific effects; for example, when resistant and suscepti-
ble alleles are equally common and equally diverse, pop-
ulation heterozygote advantage will occur if allele-specific
effects are additive, dominant or overdominant. It is diffi-
cult to generalize, without doing a specific epidemiologic
study, about how the prevalence and diversity of R and S
alleles would be likely to occur in a given population.
O'Brien et al. [12] found a spectrum of estimated effects of
Class I HLA alleles on HIV-1 disease progression, and this
spectrum seems visually to be roughly symmetric, but fur-
ther information would be required to determine plausi-
ble values of p, Θ or Π from these data. One might expect
the distribution to be skewed toward resistant alleles for
diseases that have exerted long-term selection on a
population, but it is difficult to make confident predic-
tions about such patterns without detailed knowledge of
host-pathogen coevolution.
Our results do not deny that allele-specific overdomi-
nance at HLA exists in human populations with respect to
infectious disease resistance, but simply raise doubts
about the reliability of the major evidence that has been
adduced in support of this phenomenon. Existing data
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suggest that allele-specific overdominance may exist in
some animal infectious diseases, but also that simple
dominance and other outcomes are commonly observed
[11]. Several experimental studies have examined this
question using single-strain infections in animals, and
while suggestions of allele-specific overdominance have
been made, none of the studies has been entirely convinc-
ing. Doherty and Zinkernagel [20] demonstrated using
congenic mice that MHC homozygotes had more vigor-
ous immune responses to lymphocytic choriomeningitis
virus (LCMV) than the corresponding homozygotes, but
since the pathology of the infection they used is due to the
immune response, the enhanced immune response actu-
ally resulted in reduced survival. A study in mice of resist-
ance to Toxoplasma gondii showed that F1 offspring of two
genetically divergent parent strains were more resistant
than either parent strain, but there seems to be no demon-
stration that heterozygosity at an MHC locus is responsi-
ble [18], while another reference [19] that has been cited
[10] as showing overdominance at MHC in the same host-
pathogen system does not appear to address the question
directly. A study of Marek's disease virus in chickens seems
to demonstrate allele-specific overdominance at the MHC
using defined genetic backgrounds, but the report does
not clearly specify how homogeneous the genetic back-
ground was in these experiments [21].
From the perspective of the population genetics debate
concerning the role of overdominance in maintaining
polymorphism at the MHC, we should note that this
mechanism requires allele-specific overdominance for to-
tal fitness, not for resistance to individual diseases. As not-
ed by Doherty and Zinkernagel [4], simple dominance for
resistance to each of several diseases can create allele-spe-
cific overdominance for total fitness, if different alleles
confer resistance to different diseases [10,31]. For these
reasons, our results, while relevant to the longstanding de-
bate over the relative importance of various kinds of bal-
ancing selection in maintaining MHC diversity [32], raise
doubts about only one of several lines of evidence for the
overdominance hypothesis.
Simple and accurate methods exist to determine for a sin-
gle pair of alleles how the three possible genotypes (2 ho-
mozygotes and one heterozygote) affect disease outcome,
and these methods have been used frequently in the liter-
ature on autoimmunity and HLA [28–30] and once (to
our knowledge) in the HLA-infectious disease literature
[33]. It is of additional interest for epidemiologists, im-
munologists, vaccine designers and evaluators, and popu-
lation geneticists to know whether HLA heterozygosity in
general improves the immune response to and outcome
of infectious diseases. To answer this question in a mean-
ingful way, it will be necessary to develop improved meth-
ods that estimate the effect of heterozygosity while
conditioning on the alleles involved. Meanwhile, findings
of population heterozygote advantage should not be in-
terpreted as confirming the mechanism of allele-specific
overdominance.
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Appendix
In this appendix we prove that the relative risk defined in
Equation (3) is increasing in p and Θ, and decreasing in Π.
As a preliminary result that will be useful later, note that
 and  .
Proof that the relative risk is increasing in p. We must show
that  . To do so, we calculate:
By definition, p and Π + Θ are each between zero and one,
and all of the parameters Π, Θ, a, b, and c are positive; and
by assumption, a ≤ b ≤ c. Therefore; therefore, all terms in
the partial derivative are positive, so the relative risk is in-
creasing in p. QED.
Proof that relative risk is decreasing in Π. Since RR = fhet/
fhom, it is sufficient to show that the numerator, fhet, is de-
creasing in Π and the denominator, fhom, is increasing in
Π. (This is intuitively clear: fhet is the weighted average of
the risk of individuals in the 2nd, 3rd, and 4th columns of
Table 1; increasing Π reduces the weight on the highest-
risk category, the 4th column with risk cx, thereby reducing
the weighted average. Similarly, increasing Π increases the
representation of RR homozygotes among homozygotes,
thereby increasing the average risk of homozygotes.) For-
mally: first, we show that fhet, is decreasing in Π, namely
that  . Taking the partial derivative and rearrang-
ing we find:
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This is justified as follows: The first term is positive by de-
fnition. Inside the curly brackets in the penultimate line
above, we have the sum of two terms, each of which itself
is the product of a nonpositive term and a nonnegative
term; thus, the curly brackets are nonpositive. Specifically,
 and   are both nonpositive because we
assumed a ≤ b ≤ c. [(1 - p)2 - Θ] is nonnegative as noted at
the beginning of the appendix. The term in curly brackets
is nonpositive, and the term outside is positive, so the
whole expression is nonpositive, as stated.
It is apparent by inspection that the denominator of the
relative risk, fhom, is increasing in Π. Since the numerator
of the relative risk is nonincreasing in Π, and the denom-
inator of the relative risk is increasing, the relative risk is
decreasing in Π.
The argument that the relative risk is increasing in Θ is ex-
actly symmetric to the argument for Π.
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